GlassScriptPhysician profile
Margaret Layo
NPI 1184225401
$3,745.08
in general payments reported to CMS, 2019-2025
34 companies · $24.58 in 2025
The $24.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $1,001 · 2023: $1,782 · 2024: $411 · 2025: $24.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $433.52 | 2021-2024 | Mounjaro, Jardiance |
| Cequr Corporation | $410.02 | 2022-2023 | Cequr Simplicity |
| Novo Nordisk INC | $370.30 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $314.86 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $249.01 | 2021-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.74 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $217.81 | 2022-2023 | Quviviq |
| Abbvie INC. | $186.93 | 2023-2024 | |
| Glaxosmithkline, LLC. | $164.07 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $147.73 | 2021-2023 | |
| Tolmar, INC. | $114.23 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $86.67 | 2021-2024 | |
| Dexcom, INC. | $76.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $65.82 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $64.90 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.58 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $51.00 | 2023 | Veozah, Myrbetriq |
| Pfizer INC. | $49.01 | 2022-2023 | |
| Zealand Pharma US, INC. | $43.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.47 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $41.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.43 | 2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $34.04 | 2021-2022 | |
| Halozyme INC | $33.05 | 2023 | |
| Esperion Therapeutics, INC. | $32.88 | 2021 | |
| Merck Sharp & Dohme LLC | $32.29 | 2023 | Gardasil 9, Vaxneuvance |
| Bausch Health US, LLC | $24.92 | 2023 | Wellbutrin, Aplenzin |
| Exact Sciences Corporation | $23.90 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $23.19 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.12 | 2022 | |
| Medtronic, INC. | $22.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.33 | 2021 | |
| Mannkind Corporation | $15.91 | 2023 | Afrezza |
| Shield Therapeutics INC | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Layo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.